炎症是很多肺部常见疾病如急性肺损伤、肺炎、肺纤维化、哮喘、肺癌等的共同病理生理学基础,靶向炎症反应启动及消退的发生机制将为治疗肺部炎症性疾病提供新的方向。炎症消退反应被证明是由一系列特异性促炎症消退脂质介质 (specialized proresolving lipid mediators,SPMs)参与的主动过程。Maresin 1 作为 SPMs 家族的一员,源自内源性二十二碳六烯酸(docosahexenoic acid)的兼具抗炎和促炎症消退活性的脂质活性介质。在许多炎症性疾病中均发挥了保护性作用。本文将结合近期的研究工作对 Maresin 1 在肺部炎症性疾病中的作用进行简要综述。

Inflammation is the common pathophysiological basis for many prevalent lung diseases, such as acute lung injury (ALI), pneumonia, pulmonary fibrosis, asthma and lung cancer. Targeting the mechanism of the initiation, development and resolution of the inflammation may provide new strategies for the treatment of pulmonary inflammatory diseases. Inflammatory resolution has been considered as an active process involving a series of specialized proresolving lipid mediators (SPMs). As a member of the SPMs family, maresin 1 is a bioactive lipid mediator derived from docosahexaenoic acid (DHA) with both anti-inflammatory and proresolving actions. Here, we briefly review the role of maresin 1 in pulmonary inflammatory diseases,hoping to pave a way for further investigation of new therapeutic strategies.